Mabtas 500 Infusion
Regulated Product — Business License RequiredB2B and export product information for licensed and authorized business customers. Contact our team regarding bulk supply, documentation, and applicable commercial, import, and export requirements. This page is not a storefront and no purchasing, checkout, or pricing is offered here.
Product Overview
Mabtas 500 Infusion contains rituximab, a monoclonal antibody that targets the CD20 protein on certain immune cells. Its labelling describes it for the treatment of non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukaemia, and for rheumatoid arthritis and the vasculitis conditions granulomatosis with polyangiitis and microscopic polyangiitis. It is given as an infusion under the supervision of a doctor.
Product Information
The following description reflects information associated with rituximab and this product’s labelling. It has not been independently clinically verified by SDO Pharma and is provided for business and product-identification purposes only. It is not medical advice and does not replace the manufacturer’s official prescribing information.
Described Uses
- Described for the treatment of non-Hodgkin lymphoma (NHL)
- Described for the treatment of chronic lymphocytic leukaemia
- Described for the treatment of rheumatoid arthritis
- Described for the treatment of granulomatosis with polyangiitis and microscopic polyangiitis
Described Dosage & Administration
- Administered only by a doctor as an infusion — not self-administered
- The dose and duration are set by the doctor and may change according to treatment progress
- Benefits are described as taking months to become visible; the course should be completed
Described Side Effects
Commonly described side effects include:
- Infusion-site reactions and infusion-related reactions
- Headache
- Weakness
- Infection
- Chills and fever
- Abdominal pain
- Back pain
Infusion-related reactions are described as needing monitoring during and after the infusion. Any severe, persistent, or unexpected reaction requires prompt medical attention.
Precautions
- The doctor should be told about any heart, kidney, or liver problems, any infection, or any planned surgery or vaccination
- It is described as not recommended during pregnancy or breastfeeding
- Effective contraception should be used by patients of any sex
- Any persistent or severe side effect should be reviewed by a clinician
This summary is provided for informational purposes only and does not replace the manufacturer’s official product labelling or professional medical advice.
B2B, Import & Export Enquiries
SDO Pharma supports business enquiries for pharmaceutical products, including bulk and export supply, subject to applicable licensing, regulatory, import, and export requirements. Requirements vary according to the destination market and the nature of the transaction.
We do not claim that this product is available for import into every country, and we do not claim FDA, UAE, EU, or other specific regulatory approval unless independently verified. Applicable documentation — including a valid Drug License, tax registration, and Importer Exporter Code (IEC) where relevant — is discussed directly with our team as part of the enquiry process. This is a regulated / prescription-status product supplied only to licensed and authorized business customers; SDO Pharma does not sell it directly to individual patients or consumers. See our Regulated Products Policy.
Request Product Information
Interested in this product for your business? Submit your enquiry and our team will contact you regarding bulk supply, documentation, and applicable requirements.
Frequently Asked Questions
Per its labelling it contains rituximab, an anti-CD20 monoclonal antibody used to treat non-Hodgkin lymphoma, chronic lymphocytic leukaemia, rheumatoid arthritis, and the vasculitis conditions granulomatosis with polyangiitis and microscopic polyangiitis. SDO Pharma has not independently verified the manufacturer’s claims and does not claim any specific regulatory approval unless independently confirmed.
Its labelling states it is administered by a doctor as an infusion, at the dose and schedule set by the treating team. It is not self-administered, and benefits may take months to appear.
Licensed and authorized business customers can submit the product enquiry form above or contact our team directly. Product availability, documentation, and supply arrangements are confirmed per enquiry.
Availability depends on the destination market’s regulatory requirements and cannot be confirmed without a direct enquiry. See our B2B, Import & Export Enquiries section above.
Related Product Categories
SDO Pharma works across several pharmaceutical and healthcare product categories for business customers.